Equities research analysts expect Axovant Sciences (NASDAQ:AXON) to announce earnings of ($0.39) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Axovant Sciences’ earnings. The lowest EPS estimate is ($0.49) and the highest is ($0.27). Axovant Sciences reported earnings per share of ($0.53) during the same quarter last year, which indicates a positive year-over-year growth rate of 26.4%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, June 12th.
According to Zacks, analysts expect that Axovant Sciences will report full year earnings of ($2.22) per share for the current year, with EPS estimates ranging from ($2.32) to ($2.09). For the next financial year, analysts anticipate that the business will report earnings of ($1.83) per share, with EPS estimates ranging from ($2.65) to ($1.22). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Axovant Sciences.
A number of equities analysts have issued reports on AXON shares. Zacks Investment Research raised shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a report on Wednesday, January 31st. Cowen reissued a “hold” rating on shares of Axovant Sciences in a report on Tuesday, February 13th. Oppenheimer reissued a “hold” rating on shares of Axovant Sciences in a report on Tuesday, February 13th. ValuEngine raised shares of Axovant Sciences from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Chardan Capital raised shares of Axovant Sciences from a “sell” rating to a “neutral” rating and set a $2.50 target price on the stock in a report on Wednesday, January 10th. One analyst has rated the stock with a sell rating, nine have given a hold rating and four have issued a buy rating to the stock. Axovant Sciences has an average rating of “Hold” and a consensus price target of $13.61.
In other Axovant Sciences news, Director George Bickerstaff purchased 25,000 shares of the business’s stock in a transaction dated Tuesday, February 27th. The shares were bought at an average price of $1.50 per share, with a total value of $37,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 72.40% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN raised its holdings in shares of Axovant Sciences by 135.6% during the third quarter. Wells Fargo & Company MN now owns 53,695 shares of the biotechnology company’s stock valued at $369,000 after buying an additional 30,905 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Axovant Sciences by 284.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 182,676 shares of the biotechnology company’s stock worth $963,000 after purchasing an additional 135,141 shares in the last quarter. Alliancebernstein L.P. raised its holdings in Axovant Sciences by 108.8% during the fourth quarter. Alliancebernstein L.P. now owns 108,600 shares of the biotechnology company’s stock worth $572,000 after purchasing an additional 56,600 shares in the last quarter. Two Sigma Investments LP bought a new stake in Axovant Sciences during the fourth quarter worth approximately $827,000. Finally, Virtus Fund Advisers LLC bought a new stake in Axovant Sciences during the fourth quarter worth approximately $349,000. 93.01% of the stock is currently owned by institutional investors.
NASDAQ AXON traded down $0.04 during trading hours on Thursday, reaching $1.09. The company’s stock had a trading volume of 328,209 shares, compared to its average volume of 1,215,944. The company has a quick ratio of 4.58, a current ratio of 4.58 and a debt-to-equity ratio of 0.45. Axovant Sciences has a 52 week low of $1.02 and a 52 week high of $27.98. The stock has a market capitalization of $113.18, a P/E ratio of -0.60 and a beta of -0.37.
About Axovant Sciences
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.